San Francisco startup Construction Therapeutics is likewise focusing on an oral, when-everyday GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s anticipations in June whenever a mid-stage study showed typical weight loss of close to six% and it plans to start An additional